Tara.Jk
TARA.JK operates in the real estate rental, development, and operations sector, generating revenue primarily through property development and management.
Business. Protara Therapeutics Inc (TARA.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
8 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Protara Therapeutics Inc (TARA.O) has recorded a series of notable new institutional holdings, marking the first analysis for the ticker with no prior basis for delta computation. The most significant addition involves an investor acquiring 1,402,413 shares valued at approximately $7.3 million as of March 31, 2026, representing a portfolio weight of roughly 0.13%. This entry stands out as the largest single position among the newly reported holders, signaling initial institutional interest in the company's equity. Several other investors also initiated positions during the same period, further broadening the shareholder base. One holder acquired 1,005,142 shares worth approximately $5.2 million, while another took a position of 556,974 shares valued at roughly $2.9 million. Additional notable additions include holdings of 531,267 shares (approximately $2.8 million), 147,888 shares (approximately $0.77 million), 115,273 shares (approximately $0.24 million), and 36,306 shares (approximately $0.00019 million). These entries were all detected on June 20, 2026, reflecting a coordinated wave of new capital inflow. The accumulation of these positions brings the total number of top holders for Protara Therapeutics to 20. Despite this growing investor interest, the company currently has no analyst coverage and is not a member of any major indices. The firm is also characterized by a lean executive structure, with only one officer listed in the current records. This influx of new holders is significant as it establishes a baseline for institutional ownership in a company that previously lacked a track record of reported holder changes. The absence of analyst estimates or ESG ratings in the current data suggests that these early investors are making independent assessments of the company's potential. As the first recorded analysis for TARA.O, these holder changes provide the initial data points for monitoring future shifts in institutional sentiment and capital allocation.
Signals & dispatch
Composite-score breakdown
Synthesis
Protara Therapeutics Inc (TARA.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
TARA.JK exhibits a strong liquidity position, with a current ratio of 3.21, indicating the company can cover its short-term liabilities more than three times over. The company has no long-term debt, and its operating cash flow of 23.2 billion IDR supports its liquidity profile. However, the free cash flow is negative at -6.5 billion IDR, suggesting that capital expenditures are outpacing operating cash inflows.
Profitability metrics for TARA.JK are negative, with a return on equity of -0.47% and a return on assets of -0.45%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income is significantly negative at -4.9 billion IDR, which is a concern given the company's revenue of 3.7 billion IDR.
TARA.JK's revenue is not segmented by geographic region or business line in the available data, making it difficult to assess the geographic or product concentration of its operations. The company's exposure to specific markets or products is therefore unclear.
The company's growth trajectory is uncertain, as there is no forward-looking revenue guidance provided in the available data. The operating cash flow is positive, but the negative free cash flow suggests that the company is investing heavily in capital expenditures, which may be a sign of expansion or asset development. The absence of long-term debt and the low dilution risk indicate that the company is not currently relying on equity issuance to fund its operations.
TARA.JK has not disclosed any recent significant events, such as major filings or earnings transcripts, that would provide insight into its strategic direction or operational performance. The lack of recent events may indicate a stable but uneventful period for the company.
Protara Therapeutics Inc (TARA.O) has recorded a series of notable new institutional holdings, marking the first analysis for the ticker with no prior basis for delta computation. The most significant addition involves an investor acquiring 1,402,413 shares valued at approximately $7.3 million as of March 31, 2026, representing a portfolio weight of roughly 0.13%. This entry stands out as the largest single position among the newly reported holders, signaling initial institutional interest in the company's equity. Several other investors also initiated positions during the same period, further broadening the shareholder base. One holder acquired 1,005,142 shares worth approximately $5.2 million, while another took a position of 556,974 shares valued at roughly $2.9 million. Additional notable additions include holdings of 531,267 shares (approximately $2.8 million), 147,888 shares (approximately $0.77 million), 115,273 shares (approximately $0.24 million), and 36,306 shares (approximately $0.00019 million). These entries were all detected on June 20, 2026, reflecting a coordinated wave of new capital inflow. The accumulation of these positions brings the total number of top holders for Protara Therapeutics to 20. Despite this growing investor interest, the company currently has no analyst coverage and is not a member of any major indices. The firm is also characterized by a lean executive structure, with only one officer listed in the current records. This influx of new holders is significant as it establishes a baseline for institutional ownership in a company that previously lacked a track record of reported holder changes. The absence of analyst estimates or ESG ratings in the current data suggests that these early investors are making independent assessments of the company's potential. As the first recorded analysis for TARA.O, these holder changes provide the initial data points for monitoring future shifts in institutional sentiment and capital allocation.
- TARA.JK has a strong liquidity position with a current ratio of 3.21 and no long-term debt.
- The company is not generating positive returns for shareholders, with a return on equity of -0.47%.
- Free cash flow is negative, indicating that capital expenditures are outpacing operating cash inflows.
- There is no recent significant event or filing that provides insight into the company's strategic direction.
- The company's revenue is not segmented, making it difficult to assess geographic or product concentration.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, CEO and President · Stock Option (Right to Buy) → Common StockDisposed 215 687 @ $1,91exercise · 2026-06-29
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Director · Stock Option (Right to Buy) → Common StockAcquired 31 000 @ $3,94grant · 2026-06-15
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 175 000 @ $5,01grant · 2026-01-16
- VP, Controller · Stock Option (Right to Buy) → Common StockAcquired 55 000 @ $5,01grant · 2026-01-16
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 158 000 @ $5,01grant · 2026-01-16
- Director, CEO and President · Stock Option (Right to Buy) → Common StockAcquired 524 000 @ $5,01grant · 2026-01-16
- Chf Scientific Operations Off · Stock Option (Right to Buy) → Common StockAcquired 180 000 @ $5,01grant · 2026-01-16
- Chief Commercial Officer · Stock Option (Right to Buy) → Common StockAcquired 158 000 @ $5,01grant · 2026-01-16
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- TARA.JK Market data — financials · 2026-05-29
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,01 %$27M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Jesse SheffermanPresident, Chief Executive Officer, Director
Insider activity
- Director, CEO and President · Common StockOther 14 000 · 2026-06-30
- Director, CEO and President · Common StockOther 5 000 · 2026-06-30
- Director, CEO and President · Common StockOther 4 000 · 2026-06-30
- Director, CEO and President · Common StockOther 7 000 · 2026-06-30
- Director, CEO and President · Common StockOther 215 687 @ $1,91$412K · 2026-06-29
- Director, CEO and President · Common StockSold 215 687 @ $4,09$882K · 2026-06-29
- Chief Commercial Officer · Common StockOther 6 008 @ $4,34$26K · 2026-06-02
- Chief R&D Officer · Common StockSold 1 134 @ $5,40$6K · 2026-04-08
- Chief R&D Officer · Common StockSold 22 598 @ $5,26$119K · 2026-04-01
- VP, Controller · Common StockOther 1 457 @ $6,67$10K · 2026-01-26
- Chief Financial Officer · Common StockOther 3 261 @ $6,67$22K · 2026-01-26
- Director, CEO and President · Common StockOther 8 732 @ $6,67$58K · 2026-01-26
- Chf Scientific Operations Off · Common StockOther 3 724 @ $6,67$25K · 2026-01-26
- Director, CEO and President · Common StockOther 16 322 @ $5,60$91K · 2026-01-20
- Chief Financial Officer · Common StockOther 3 063 @ $5,60$17K · 2026-01-20
- Chf Scientific Operations Off · Common StockOther 6 578 @ $5,60$37K · 2026-01-20
- VP, Controller · Common StockOther 2 132 @ $5,60$12K · 2026-01-20
- Chief Commercial Officer · Common StockOther 26 000 · 2026-01-16
- Chief Financial Officer · Common StockOther 28 000 · 2026-01-16
- VP, Controller · Common StockOther 9 500 · 2026-01-16
- Chief Medical Officer · Common StockOther 26 000 · 2026-01-16
- Director, CEO and President · Common StockOther 87 000 · 2026-01-16
- Chf Scientific Operations Off · Common StockOther 30 000 · 2026-01-16
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -57.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 38.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -28.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -69.5%Derived (calculated)
- Return on assets (FY 2025-12-31): -27.4%Derived (calculated)
- Return on equity (FY 2025-12-31): -29.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 14.58xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 49.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 38.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.07xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 34.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 15.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -31.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 17.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -8.8%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Current assets (annual): USD 159.5MSEC XBRL filing
- Shares outstanding (annual): 53.59MSEC XBRL filing
- Operating cash flow (annual): USD -56.37MSEC XBRL filing
- Total liabilities (annual): USD 13.06MSEC XBRL filing
- Total assets (annual): USD 209.47MSEC XBRL filing
- Pre-tax income (annual): USD 57.35MSEC XBRL filing
- Current liabilities (annual): USD 10.94MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing